Windows 8.1 May Increase Sales This Year. Despite a not so promising previous year, Nokia Corporation (ADR) (NYSE:NOK) aims high to sell more number of phones this year as they have now introduced windows 8.1 as the operating system of the new lumia phones and more other apps to amaze the users. They are now hoping to get the position they were previously held in the mobile business all over the world and can able to challenge its main competitors in the business.Nokia Corporation (ADR) (NYSE:NOK) shares after opening at $7.59 moved to $7.78 on last trade day and at the end of the day closed at $7.58. Company price to sales ratio in past twelve months was calculated as 0.85 and price to cash ratio as 3.92. Nokia Corporation (ADR) (NYSE:NOK) showed a positive weekly performance of 0.40%.
Leading wireless carrier, Verizon Communications Inc. (NYSE:VZ) is reportedly acquiring spectrum assets worth $210 million from Cincinnati Bell Inc. . Verizon will first purchase Cincinnati Bell’s spectrum licenses which account for $194 million of the total purchase price.As reported, the deal is expected to close by the second half of this year. We believe the new spectrum acquisition will boost Verizon’s wireless infrastructure and aid in its future network development.Verizon Communications Inc. (NYSE:VZ) shares advanced 1.30% in last trading session and ended the day on $48.21. VZ return on equity ratio is recorded as 32.60% and its return on assets is 4.60%. Verizon Communications Inc. (NYSE:VZ) yearly performance is 1.99%.
AT&T Inc. (NYSE:T) wants to shut off its aging, landline phone network and move home phones to new technology but to get it done, the carrier is going to have to contend with people like Mary Ann Hardziej. AT&T Inc. (NYSE:T) shares moved up 0.69% in last trading session and was closed at $35.27, while trading in range of $34.91-$35.27. AT&T Inc. (NYSE:T) year to date performance is 2.98%.
Pfizer Inc. (NYSE:PFE) announced in early February some positive results from a randomized Phase 2 trial of palbociclib in combination with letrozole (for blocking the synthesis of estrogen) in post-menopausal women with estrogen receptor (ER) positive recurring or metastatic breast cancer that is human epidermal growth factor receptor 2 (HER2) negative. About 60 to 65 percent of breast cancers are of this type translating to about 50,000 American women a year who might benefit from palbociclib. It remains to be seen whether the Food and Drug Administration (FDA) will grant approval to the drug based on this study alone or a larger Phase 3 trial will be needed. Palbociclib has already received ‘Breakthrough Therapy’ designation in April 2013 based on interim data from this trial. Patient enrolment is currently on for a Phase 3 randomized global trial in this patient population. Pfizer Inc. (NYSE:PFE) weekly performance is -3.38%. On last trading day company shares ended up $30.87. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average is -2.42%. Analysts mean target price for the company is $34.09.
Leave a Reply